Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial
May 2, 2024
Smart Immune is a French clinical-stage biotech company developing ProTcell, a T-cell progenitor therapy platform that harnesses the patient's own thymus to rapidly re-arm the immune system against cancer and infection.
Through its patented ex vivo lymphoid technology, Smart Immune has developed a T-cell progenitor-based cell therapy platform, called the ProTcell platform. It has been designed to enable rapid and full re-arming of the immune system, so patients can fight life-threatening disorders like cancers and infections.